Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 3/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.51 |
| ▸ | EDNRB | P24530 | 2/20 | 0.51 |
| ▸ | EDNRA | P25101 | 2/20 | 0.51 |
| ▸ | SCN1A | P35498 | 2/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.48 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208173 | 0.84 | CA1 (0.53) | HCRTR1CA1CA2CA9F2 | |
| SCHEMBL2442410 | 0.83 | HCRTR1 (0.51) | HCRTR1CA1CA2CA9F2 | |
| SCHEMBL11174854 | 0.82 | CA1 (0.52) | HCRTR1CA1CA2CA9F2 | |
| SCHEMBL2371611 | 0.81 | HCRTR1 (0.50) | HCRTR1CA1CA2CA9F2 | |
| SCHEMBL3698223 | 0.79 | HCRTR1 (0.58) | HCRTR1CA1CA2CA9F2 | |
| SCHEMBL3987899 | 0.79 | F2 (0.49) | HCRTR1CA1CA2CA9F2 | |
| SCHEMBL6580093 | 0.79 | CA1 (0.61) | HCRTR1CA1CA2CA9F2 | |
| SCHEMBL27813020 | 0.78 | HCRTR1 (0.50) | HCRTR1CA1CA2CA9F2 | |
| SCHEMBL2372503 | 0.78 | HCRTR1 (0.50) | HCRTR1CA1CA2CA9F2 | |
| SCHEMBL5048491 | 0.77 | EDNRA (0.63) | CA2F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547204-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | Bayer Intellectual Property GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| WO-2011113861-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | WO | claimed |
| EP-2547204-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | Bayer Intellectual Property GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2431370-A1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-8058440-B2 | Process for producing 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011113861-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | WO | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-5274082-A | A mono- or diaminonaphthalenepolycarboxylic acid as the chelating compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1993-12-28 | — | — | US | disclosed |
| US-5196576-A | Medical imaging of liver tissue | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1993-03-23 | — | — | US | disclosed |
| US-5138039-A | Diagnosis, therapy | NIHON MEDI-PHYSICS CO., LTD (JP) | 1992-08-11 | — | — | US | disclosed |
| EP-0451824-A2 | Chelating compounds and their use | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | HCRTR1 583/4885CA1 2347/4885CA2 4658/4885 |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | STS, ARSA, TST | HCRTR1 4022/4885CA1 4599/4885CA2 3102/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | HCRTR1 469/4885CA1 2310/4885CA2 4684/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | HCRTR1 827/4885CA1 3944/4885CA2 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.